Basics Aurinia Pharmaceuticals Inc Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis. IPO Date: September 1, 2014 Sector: Healthcare Industry: Biotech Market Cap: $1.06B Activated in VL: True Average Daily Range Avg Daily Range: $0.23 | 2.74% Avg Daily Range (30 D): $0.13 | 1.65% Avg Daily Range (90 D): $0.15 | 1.81% Institutional Daily Volume Avg Daily Volume: 1.74M Avg Daily Volume (30 D): 1.12M Avg Daily Volume (90 D): 1.21M Trade Size Avg Trade Size (Sh.): 173 Avg Trade Size (Sh.) (30 D): 101 Avg Trade Size (Sh.) (90 D): 102 Institutional Trades Total Inst.Trades: 2,246 Avg Inst. Trade: $1.22M Avg Inst. Trade (30 D): $1.37M Avg Inst. Trade (90 D): $1.09M Avg Inst. Trade Volume: .11M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $1.29M Avg Closing Trade (30 D): $1.02M Avg Closing Trade (90 D): $1M Avg Closing Volume: 127.56K         News Jan 8, 2025 @ 8:35 PM New American College of Rheumatology Guidelines fo... Source: Spherix Global Insights Oct 2, 2024 @ 1:48 PM Corporate and Individual Donations Provide Much-Ne... Source: American Kidney Fund Jun 17, 2024 @ 8:46 AM Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump... Source: Zacks Equity Research May 7, 2024 @ 1:55 PM How Much Upside is Left in Aurinia (AUPH)? Wall St... Source: Zacks Equity Research May 2, 2024 @ 11:10 AM Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, To... Source: Zacks Equity Research Financials   TTM Q3 2024 Q2 2024 Basic EPS $-.16 $.1 $.01 Diluted EPS $-.16 $.1 $.01 Revenue $ 220.36M $ 67.77M $ 57.19M Gross Profit $ 192.27M $ 61.74M $ 48.28M Net Income / Loss $ -22.55M $ 14.35M $ .72M Operating Income / Loss $ -32.69M $ 11.75M $ -1.51M Cost of Revenue $ 28.09M $ 6.04M $ 8.91M Net Cash Flow $ -9.26M $ 3.74M $ -31.05M PE Ratio     Splits Oct 23, 2013:   50:1